EMA Authorised: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The European Medicines Agency has authorised Blenrep (belantamab mafodotin) for the treatment of multiple myeloma. The decision date is 05 February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 05/02/2026